BRPI0816012A2 - uso de um novo agente natural em composições cosméticas - Google Patents
uso de um novo agente natural em composições cosméticas Download PDFInfo
- Publication number
- BRPI0816012A2 BRPI0816012A2 BRPI0816012A BRPI0816012A BRPI0816012A2 BR PI0816012 A2 BRPI0816012 A2 BR PI0816012A2 BR PI0816012 A BRPI0816012 A BR PI0816012A BR PI0816012 A BRPI0816012 A BR PI0816012A BR PI0816012 A2 BRPI0816012 A2 BR PI0816012A2
- Authority
- BR
- Brazil
- Prior art keywords
- effect
- manoproteins
- cosmetic
- mannoproteins
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 239000002537 cosmetic Substances 0.000 title claims abstract description 80
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 56
- 102100024023 Histone PARylation factor 1 Human genes 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 35
- 108010005335 mannoproteins Proteins 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims description 60
- 210000004209 hair Anatomy 0.000 claims description 36
- 210000003491 skin Anatomy 0.000 claims description 29
- 239000000654 additive Substances 0.000 claims description 17
- 206010039792 Seborrhoea Diseases 0.000 claims description 16
- 230000003779 hair growth Effects 0.000 claims description 14
- 210000004207 dermis Anatomy 0.000 claims description 12
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 11
- 230000003712 anti-aging effect Effects 0.000 claims description 10
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 9
- 201000004384 Alopecia Diseases 0.000 claims description 9
- 206010000496 acne Diseases 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 210000002374 sebum Anatomy 0.000 claims description 9
- 239000000230 xanthan gum Substances 0.000 claims description 9
- 229940082509 xanthan gum Drugs 0.000 claims description 9
- 235000010493 xanthan gum Nutrition 0.000 claims description 9
- 241000233866 Fungi Species 0.000 claims description 8
- 241000235070 Saccharomyces Species 0.000 claims description 8
- 210000002615 epidermis Anatomy 0.000 claims description 8
- 230000003020 moisturizing effect Effects 0.000 claims description 8
- 230000009759 skin aging Effects 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 210000002421 cell wall Anatomy 0.000 claims description 7
- 208000024963 hair loss Diseases 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 6
- 235000013824 polyphenols Nutrition 0.000 claims description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 241000235649 Kluyveromyces Species 0.000 claims description 4
- 241000006364 Torula Species 0.000 claims description 4
- 230000003255 anti-acne Effects 0.000 claims description 4
- 230000036620 skin dryness Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 108010064983 Ovomucin Proteins 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 230000000887 hydrating effect Effects 0.000 claims description 2
- 230000003752 improving hair Effects 0.000 claims description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 16
- 239000002671 adjuvant Substances 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 description 31
- 238000003786 synthesis reaction Methods 0.000 description 30
- 102000008186 Collagen Human genes 0.000 description 22
- 108010035532 Collagen Proteins 0.000 description 22
- 229920001436 collagen Polymers 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000839 emulsion Substances 0.000 description 13
- 239000013642 negative control Substances 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 11
- 229920002674 hyaluronan Polymers 0.000 description 11
- 229960003160 hyaluronic acid Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 208000001840 Dandruff Diseases 0.000 description 10
- 210000004761 scalp Anatomy 0.000 description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 102000016942 Elastin Human genes 0.000 description 8
- 108010014258 Elastin Proteins 0.000 description 8
- 229920002549 elastin Polymers 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000012460 protein solution Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000001804 emulsifying effect Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 101001047783 Homo sapiens Histone PARylation factor 1 Proteins 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 150000002433 hydrophilic molecules Chemical class 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000007908 nanoemulsion Substances 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000037312 oily skin Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 230000003760 hair shine Effects 0.000 description 2
- 230000003699 hair surface Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- -1 stick Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000000380 Nyssa aquatica Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- FRGAIZLZPOROJH-BKIJVIAGSA-N [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-hydroxy-3-[2-hydroxy-3-(2-hydroxy-3-octadecanoyloxypropoxy)propoxy]propoxy]oxan-2-yl]methyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)CO[C@H]1O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@H]1O FRGAIZLZPOROJH-BKIJVIAGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000002086 anti-sebum Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 208000024349 endocrine alopecia Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002231 macronucleus Anatomy 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000011514 vinification Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Cosmetics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0706701A FR2921260B1 (fr) | 2007-09-25 | 2007-09-25 | Utilisation d'un nouvel agent naturel dans des compositions cosmetiques |
PCT/FR2008/001319 WO2009074735A2 (fr) | 2007-09-25 | 2008-09-23 | Utilisation d'un nouvel agent naturel dans des compositions cosmetiques |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0816012A2 true BRPI0816012A2 (pt) | 2019-10-01 |
Family
ID=39537487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0816012A BRPI0816012A2 (pt) | 2007-09-25 | 2008-09-23 | uso de um novo agente natural em composições cosméticas |
Country Status (19)
Country | Link |
---|---|
US (2) | US9636290B2 (fr) |
EP (2) | EP2567688B1 (fr) |
JP (1) | JP5691053B2 (fr) |
KR (1) | KR101603051B1 (fr) |
CN (1) | CN101815500B (fr) |
AU (1) | AU2008334527B2 (fr) |
BR (1) | BRPI0816012A2 (fr) |
CA (1) | CA2700424C (fr) |
DK (2) | DK2203153T3 (fr) |
ES (2) | ES2549534T3 (fr) |
FR (1) | FR2921260B1 (fr) |
HR (2) | HRP20161625T1 (fr) |
HU (2) | HUE025403T2 (fr) |
LT (1) | LT2203153T (fr) |
MX (1) | MX2010003258A (fr) |
PL (2) | PL2203153T3 (fr) |
RU (1) | RU2491051C2 (fr) |
SI (2) | SI2567688T1 (fr) |
WO (1) | WO2009074735A2 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10168393B2 (en) | 2014-09-25 | 2019-01-01 | Lockheed Martin Corporation | Micro-vacancy center device |
US9614589B1 (en) | 2015-12-01 | 2017-04-04 | Lockheed Martin Corporation | Communication via a magnio |
US9910105B2 (en) | 2014-03-20 | 2018-03-06 | Lockheed Martin Corporation | DNV magnetic field detector |
US9541610B2 (en) | 2015-02-04 | 2017-01-10 | Lockheed Martin Corporation | Apparatus and method for recovery of three dimensional magnetic field from a magnetic detection system |
US10088336B2 (en) | 2016-01-21 | 2018-10-02 | Lockheed Martin Corporation | Diamond nitrogen vacancy sensed ferro-fluid hydrophone |
US10012704B2 (en) | 2015-11-04 | 2018-07-03 | Lockheed Martin Corporation | Magnetic low-pass filter |
US9853837B2 (en) | 2014-04-07 | 2017-12-26 | Lockheed Martin Corporation | High bit-rate magnetic communication |
US9910104B2 (en) | 2015-01-23 | 2018-03-06 | Lockheed Martin Corporation | DNV magnetic field detector |
US10088452B2 (en) | 2016-01-12 | 2018-10-02 | Lockheed Martin Corporation | Method for detecting defects in conductive materials based on differences in magnetic field characteristics measured along the conductive materials |
US9638821B2 (en) | 2014-03-20 | 2017-05-02 | Lockheed Martin Corporation | Mapping and monitoring of hydraulic fractures using vector magnetometers |
CA2945016A1 (fr) | 2014-04-07 | 2015-10-15 | Lockheed Martin Corporation | Circuit generateur de champ magnetique a commande orientee vers l'efficacite energetique |
WO2016118756A1 (fr) | 2015-01-23 | 2016-07-28 | Lockheed Martin Corporation | Appareil et procédé pour mesure de magnétométrie à haute sensibilité et traitement de signal dans un système de détection magnétique |
CA2975103A1 (fr) | 2015-01-28 | 2016-08-04 | Stephen M. SEKELSKY | Charge d'alimentation in situ |
EP3250887A4 (fr) | 2015-01-28 | 2018-11-14 | Lockheed Martin Corporation | Procédés et systèmes de navigation magnétique à l'aide d'un réseau de distribution électrique et d'un réseau de communication |
GB2550809A (en) | 2015-02-04 | 2017-11-29 | Lockheed Corp | Apparatus and method for estimating absolute axes' orientations for a magnetic detection system |
WO2017087014A1 (fr) | 2015-11-20 | 2017-05-26 | Lockheed Martin Corporation | Appareil et procédé de détection de l'hypersensibilité d'un champ magnétique |
WO2017087013A1 (fr) | 2015-11-20 | 2017-05-26 | Lockheed Martin Corporation | Appareil et procédé de traitement en boucle fermée pour un système de détection magnétique |
WO2017127081A1 (fr) | 2016-01-21 | 2017-07-27 | Lockheed Martin Corporation | Capteur azote-lacune de diamant avec circuit sur le diamant |
AU2016388316A1 (en) | 2016-01-21 | 2018-09-06 | Lockheed Martin Corporation | Diamond nitrogen vacancy sensor with common RF and magnetic fields generator |
WO2017127090A1 (fr) | 2016-01-21 | 2017-07-27 | Lockheed Martin Corporation | Sensibilité magnétique supérieure par manipulation de fluorescence par contrôle de spectre de phonons |
GB2562957A (en) | 2016-01-21 | 2018-11-28 | Lockheed Corp | Magnetometer with light pipe |
WO2017127096A1 (fr) | 2016-01-21 | 2017-07-27 | Lockheed Martin Corporation | Capteur d'azote-lacune de diamant avec doubles sources rf |
WO2017127097A1 (fr) | 2016-01-21 | 2017-07-27 | Lockheed Martin Corporation | Magnétomètre doté d'une diode électroluminescente |
WO2017127079A1 (fr) | 2016-01-21 | 2017-07-27 | Lockheed Martin Corporation | Détection d'anomalies magnétiques de vecteur ca avec des centres azote-lacune du diamant |
WO2017173241A1 (fr) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Composition de désinfectant comprenant un principe actif probiotique/prébiotique |
EP3436156A1 (fr) | 2016-03-31 | 2019-02-06 | Gojo Industries, Inc. | Composition nettoyante stimulant les peptides antimicrobiens |
US20170343621A1 (en) | 2016-05-31 | 2017-11-30 | Lockheed Martin Corporation | Magneto-optical defect center magnetometer |
US10571530B2 (en) | 2016-05-31 | 2020-02-25 | Lockheed Martin Corporation | Buoy array of magnetometers |
US10345395B2 (en) | 2016-12-12 | 2019-07-09 | Lockheed Martin Corporation | Vector magnetometry localization of subsurface liquids |
US10330744B2 (en) | 2017-03-24 | 2019-06-25 | Lockheed Martin Corporation | Magnetometer with a waveguide |
US10228429B2 (en) | 2017-03-24 | 2019-03-12 | Lockheed Martin Corporation | Apparatus and method for resonance magneto-optical defect center material pulsed mode referencing |
US10408890B2 (en) | 2017-03-24 | 2019-09-10 | Lockheed Martin Corporation | Pulsed RF methods for optimization of CW measurements |
US10338163B2 (en) | 2016-07-11 | 2019-07-02 | Lockheed Martin Corporation | Multi-frequency excitation schemes for high sensitivity magnetometry measurement with drift error compensation |
US10677953B2 (en) | 2016-05-31 | 2020-06-09 | Lockheed Martin Corporation | Magneto-optical detecting apparatus and methods |
US10345396B2 (en) | 2016-05-31 | 2019-07-09 | Lockheed Martin Corporation | Selected volume continuous illumination magnetometer |
US10145910B2 (en) | 2017-03-24 | 2018-12-04 | Lockheed Martin Corporation | Photodetector circuit saturation mitigation for magneto-optical high intensity pulses |
US10359479B2 (en) | 2017-02-20 | 2019-07-23 | Lockheed Martin Corporation | Efficient thermal drift compensation in DNV vector magnetometry |
US10527746B2 (en) | 2016-05-31 | 2020-01-07 | Lockheed Martin Corporation | Array of UAVS with magnetometers |
US10281550B2 (en) | 2016-11-14 | 2019-05-07 | Lockheed Martin Corporation | Spin relaxometry based molecular sequencing |
US10371765B2 (en) | 2016-07-11 | 2019-08-06 | Lockheed Martin Corporation | Geolocation of magnetic sources using vector magnetometer sensors |
US10317279B2 (en) | 2016-05-31 | 2019-06-11 | Lockheed Martin Corporation | Optical filtration system for diamond material with nitrogen vacancy centers |
US10274550B2 (en) | 2017-03-24 | 2019-04-30 | Lockheed Martin Corporation | High speed sequential cancellation for pulsed mode |
JP2020500860A (ja) | 2016-11-23 | 2020-01-16 | ゴジョ・インダストリーズ・インコーポレイテッド | プロバイオティック/プレバイオティックな有効成分を含む消毒薬組成物 |
US10459041B2 (en) | 2017-03-24 | 2019-10-29 | Lockheed Martin Corporation | Magnetic detection system with highly integrated diamond nitrogen vacancy sensor |
US10338164B2 (en) | 2017-03-24 | 2019-07-02 | Lockheed Martin Corporation | Vacancy center material with highly efficient RF excitation |
US10379174B2 (en) | 2017-03-24 | 2019-08-13 | Lockheed Martin Corporation | Bias magnet array for magnetometer |
US10371760B2 (en) | 2017-03-24 | 2019-08-06 | Lockheed Martin Corporation | Standing-wave radio frequency exciter |
WO2019158637A1 (fr) * | 2018-02-14 | 2019-08-22 | Danstar Ferment Ag | Compositions d'extrait de levure pour le traitement de matières kératiniques |
WO2020004568A1 (fr) * | 2018-06-28 | 2020-01-02 | アサヒグループホールディングス株式会社 | Promoteur de production d'équol et composition alimentaire ou de boisson le comprenant pour favoriser la production d'équol |
CN111297725A (zh) * | 2018-12-11 | 2020-06-19 | 安琪酵母股份有限公司 | 恢复皮肤屏障功能的护肤组合物及其制备方法和应用 |
FR3125718B1 (fr) | 2021-08-02 | 2025-04-04 | Soc Ind Limousine Dapplication Biologique | Principe actif comprenant des oligo-glucanes issus de la fraction cytosolique de Saccharomyces cerevisiae et ses utilisations cosmétiques |
WO2024214363A1 (fr) * | 2023-04-14 | 2024-10-17 | 三菱商事ライフサイエンス株式会社 | Composition topique contenant un extrait de levure |
WO2024232416A1 (fr) * | 2023-05-09 | 2024-11-14 | 三菱商事ライフサイエンス株式会社 | Composition de produit cosmétique utilisant une paroi cellulaire de levure |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2726284B1 (fr) | 1994-10-31 | 1996-12-27 | Inst Oenologie | Produit biologique pour la stabilisation physico-chimique d'un vin |
EP0790316A3 (fr) * | 1996-02-16 | 1999-02-10 | Quest International B.V. | Emulsifiant à partir de la levure |
GB9608145D0 (en) * | 1996-04-19 | 1996-06-26 | British Tech Group | Wound healing |
FR2750434B1 (fr) | 1996-06-26 | 1998-08-21 | Applic De Rech Et De Conseils | Produit de stabilisation proteique des vins |
US6358516B1 (en) * | 1998-08-21 | 2002-03-19 | Norris R. Harod | One-step system for cleansing, conditioning, and treating the skin |
US8003782B1 (en) * | 1999-02-01 | 2011-08-23 | Dermal Research Laboratories, Inc. | Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
DE19911056B9 (de) * | 1999-03-12 | 2005-09-08 | Biotec Asa | Kosmetische Zubereitungen und deren Verwendung |
FR2800076B1 (fr) | 1999-10-22 | 2003-11-14 | Lesaffre & Cie | Mannoproteines solubles |
AR027016A1 (es) | 1999-12-21 | 2003-03-12 | Dsm Nv | Proceso para la estabilizacion de vino |
FR2802812B1 (fr) * | 1999-12-22 | 2002-08-23 | Serobiologiques Lab Sa | Utilisation de residus issus de la fabrication du vin pour la fabrication de preparations cosmetiques et/ou pharmaceutiques. |
FR2804864B1 (fr) | 2000-02-11 | 2003-04-04 | Serobiologiques Lab Sa | Extraits de residus issus de la fabrication du vin et leur utilisation en cosmetique ou pharmacologie |
EP1132399A1 (fr) | 2000-03-08 | 2001-09-12 | Universitair Medisch Centrum Utrecht | Mannoprotéines et produits similaires pour la modulation de la migration des neutrophiles |
EP1414865B1 (fr) * | 2000-08-03 | 2014-04-09 | Abac R & D Ag | Isolation de particules de glucane et utilisations associees |
AUPS052802A0 (en) * | 2002-02-15 | 2002-03-07 | Praxis Pharmaceuticals International Pty Ltd | Carbohydrate-based anti-wrinkle and tissue remodelling compounds |
CA2483000C (fr) * | 2002-04-25 | 2011-10-11 | Christine Garbers | Compositions de soins buccaux contenant de l'ovomucine |
AU2003256329A1 (en) * | 2002-06-27 | 2004-01-19 | University Of Washington | Use of adhesion molecules as bond stress-enhanced nanoscale binding switches |
US20070269537A1 (en) * | 2003-02-10 | 2007-11-22 | Bioderm Research | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System |
WO2006036817A2 (fr) | 2004-09-24 | 2006-04-06 | Microbia, Inc. | Variants fongiques et utilisations correspondantes |
EP1838836A1 (fr) | 2004-12-23 | 2007-10-03 | DSMIP Assets B.V. | Procédé d'amélioration de l'activité de mannoprotéines lors de la stabilisation du vin |
JP4954203B2 (ja) | 2005-09-22 | 2012-06-13 | サントリーホールディングス株式会社 | 細胞壁マンノプロテインをコードする遺伝子及びその用途 |
GB0609901D0 (en) * | 2006-05-18 | 2006-06-28 | Sinclair Pharmaceuticals Ltd | Method |
JP2008222655A (ja) * | 2007-03-14 | 2008-09-25 | Asahi Breweries Ltd | 皮膚外用剤 |
-
2007
- 2007-09-25 FR FR0706701A patent/FR2921260B1/fr active Active
-
2008
- 2008-09-23 HU HUE12190685A patent/HUE025403T2/en unknown
- 2008-09-23 ES ES12190685.3T patent/ES2549534T3/es active Active
- 2008-09-23 PL PL08860035T patent/PL2203153T3/pl unknown
- 2008-09-23 JP JP2010525388A patent/JP5691053B2/ja active Active
- 2008-09-23 SI SI200831505T patent/SI2567688T1/sl unknown
- 2008-09-23 LT LTEP08860035.8T patent/LT2203153T/lt unknown
- 2008-09-23 ES ES08860035.8T patent/ES2608492T3/es active Active
- 2008-09-23 WO PCT/FR2008/001319 patent/WO2009074735A2/fr active Application Filing
- 2008-09-23 AU AU2008334527A patent/AU2008334527B2/en active Active
- 2008-09-23 PL PL12190685T patent/PL2567688T3/pl unknown
- 2008-09-23 CA CA2700424A patent/CA2700424C/fr active Active
- 2008-09-23 KR KR1020107006905A patent/KR101603051B1/ko active Active
- 2008-09-23 HR HRP20161625TT patent/HRP20161625T1/hr unknown
- 2008-09-23 EP EP12190685.3A patent/EP2567688B1/fr active Active
- 2008-09-23 EP EP08860035.8A patent/EP2203153B1/fr active Active
- 2008-09-23 CN CN2008801087344A patent/CN101815500B/zh active Active
- 2008-09-23 US US12/679,777 patent/US9636290B2/en active Active
- 2008-09-23 HU HUE08860035A patent/HUE029832T2/en unknown
- 2008-09-23 SI SI200831725A patent/SI2203153T1/sl unknown
- 2008-09-23 DK DK08860035.8T patent/DK2203153T3/en active
- 2008-09-23 DK DK12190685.3T patent/DK2567688T3/en active
- 2008-09-23 MX MX2010003258A patent/MX2010003258A/es active IP Right Grant
- 2008-09-23 RU RU2010116160/15A patent/RU2491051C2/ru active
- 2008-09-23 BR BRPI0816012A patent/BRPI0816012A2/pt not_active Application Discontinuation
-
2015
- 2015-09-21 HR HRP20150996TT patent/HRP20150996T1/hr unknown
-
2016
- 2016-10-31 US US15/338,972 patent/US10292926B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10292926B2 (en) | Use of a novel natural agent in cosmetic compositions | |
RU2491910C2 (ru) | Применение натуральных активных веществ в косметических или терапевтических композициях | |
ES2856480T3 (es) | Utilizaciones cosméticas de la swertiamarina | |
JP2020528874A (ja) | 皮膚及び/又は粘膜を水和させるためのネフェリウム・ラパセウム(nephelium lappaceum)の果皮の抽出物の使用 | |
JP2022511023A (ja) | シスツス・モンスペリエンシス(Cistus monspeliensis)の抽出物の新規な化粧品的及び皮膚科学的使用 | |
CN118613247A (zh) | 新颖用途 | |
ES2753401T3 (es) | Uso cosmético de un extracto de Polygonum bistorta | |
CN105636653A (zh) | 圭亚那塔皮漆木提取物的化妆品或皮肤病学用途 | |
KR20170118885A (ko) | 각질세포의 지질 함유량 증가를 위한 조성물 | |
KR20220044488A (ko) | 분홍바늘꽃 추출물의 신규 화장료 용도 | |
CH717410A2 (de) | Verfahren und personalisiertes dermoästhetisches System, um mehrere kosmetische Hautprobleme mit einer einzigen Behandlung zu behandeln. | |
BR102016008597A2 (pt) | Cosmetic and / or dermatological compositions understanding biogenic systems, production process and its use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |